-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Breast cancer (BC) is a key health problem in the world, with approximately 17 million new confirmed cases every year
.
The current treatment options for BC are mainly the strategy of combining surgery and local radiotherapy with anticancer drugs
Breast cancer (BC) is a key health problem in the world, with approximately 17 million new confirmed cases every year
However, many patients will eventually develop a more aggressive form of malignancy and develop resistance to the most commonly used treatment strategies
.
Therefore, it is particularly important to identify new predictive and prognostic biomarkers to guide the management of BC radiotherapy resistance in the clinical treatment of BC
manage
Classical epigenetic mechanisms involve histone modification, chromatin remodeling, and DNA methylation
.
Due to the dynamic nature of the epigenome, the identification of epigenetic modifications may contribute to the sensitivity of radiotherapy
ENC1 is significantly overexpressed in BC tissues and is closely related to the patient's radiotherapy response
ENC1 is significantly overexpressed in BC tissues and is closely related to the patient's radiotherapy responseThis study aims to analyze the regulatory role of ENC1 in BC radiotherapy resistance
.
Bioinformatics prediction and immunohistochemical staining show that overexpression of ENC1 can promote the transfer of BC to bone and brain
This study aims to analyze the regulatory role of ENC1 in BC radiotherapy resistance
Inhibition of ENC1 can increase the sensitivity of BC cells to radiotherapy
Inhibition of ENC1 can increase the sensitivity of BC cells to radiotherapyENC1 expression is regulated by SE (Super Enhancer) ~10kb long
.
The researchers found that the deletion of the distal end of ENC1-SE reduces the expression of ENC1 and inhibits the malignancy of BC cells and their resistance to radiotherapy
All in all, the results of this study indicate that the overexpression of ENC1 is mediated by SE and downstream TCF4, which can enhance the Hippo/YAP1/TAZ signaling pathway
.
Targeting this pathway may be a therapeutic strategy to reduce BC radiotherapy resistance
Aberrant super-enhancer-driven oncogene ENC1 promotes the radio-resistance of breast carcinoma.
Leave a message here
